You are in PORTALS Cardiac Imaging Medtronic Releases New Data from MVP Trial on ICDs at Heart Rhythm 2010

Medtronic Releases New Data from MVP Trial on ICDs at Heart Rhythm 2010

E-mail Print PDF


Medtronic Medtronic has released new data from the MVP (Managed Ventricular Pacing) trial at Heart Rhythm 2010, as part of Medtronic's leading clinical portfolio to reduce appropriate and inappropriate shocks.

In the MVP trial, implantable defibrillator patients receiving anti-tachycardia pacing (ATP) were less likely to have health care utilization after treatment as compared to those receiving shock therapy.

Michael O. Sweeney, M.D., Cardiac Pacing and Heart Failure Device Therapies, Brigham and Women's Hospital in Boston, said "This multicenter, international MVP Trial data shows the health care use burden and indicates that both appropriate and inappropriate shocks frequently are associated with hospitalization or urgent care visits."

Implantable defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds), known as ventricular arrhythmias, are 98 percent effective in stopping life-threatening fast or irregular heart beats.

Further, the MVP trial shows that about 24 percent of patients who receive painless anti-tachycardia pacing (ATP) to terminate a life-threatening arrhythmia had health care use within three days of those treated episodes.

These signals are relayed buying clomid online safe which then is by a number of such as medial preoptic and paraventricular nulcei.